Associations of semaglutide with incidence and recurrence of alcohol use disorder in real-world population

Alcohol use disorders are among the top causes of the global burden of disease, yet therapeutic interventions are limited. Reduced desire to drink in patients treated with semaglutide has raised interest regarding its potential therapeutic benefits for alcohol use disorders. In this retrospective cohort study of electronic health records of 83,825 patients with obesity, we show that semaglutide compared with other anti-obesity medications is associated with a 50%-56% lower risk for both the incidence and recurrence of alcohol use disorder for a 12-month follow-up period. Consistent reductions were seen for patients stratified by gender, age group, race and in patients with and without type 2 diabetes. Similar…

• CC
  Case Comprehensive Cancer Center, Case Western Reserve University

  Award: CA043703
• NI
  National Institute on Alcohol Abuse and Alcoholism

  Award: AA029831
• NC
  National Cancer Institute

  Awards: CA043703, CA2332216, CA221718, CA043703, CA2332216